@article{ThongDoegeWeisseretal.2023,
  author    = {Thong, Melissa S. Y. and Doege, Daniela and Weißer, Linda and Koch-Gallenkamp, Lena and Jansen, Lina and Bertram, Heike and Eberle, Andrea and Holleczek, Bernd and Nennecke, Alice and Waldmann, Annika and Zeissig, Sylke Ruth and Brenner, Hermann and Arndt, Volker},
  title     = {Persisting deficits in health-related quality of life of colorectal cancer survivors 14-24 years post-diagnosis: a population-based study},
  series = {Current Oncology},
  volume    = {30},
  journal   = {Current Oncology},
  number    = {3},
  issn      = {1718-7729},
  doi       = {10.3390/curroncol30030257},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-311084},
  pages     = {3373 -- 3390},
  year      = {2023},
  abstract  = {(1) Background: The health-related quality of life (HRQOL) of colorectal cancer (CRC) survivors >10 years post-diagnosis is understudied. We aimed to compare the HRQOL of CRC survivors 14-24 years post-diagnosis to that of age- and sex-matched non-cancer controls, stratified by demographic and clinical factors. (2) Methods: We used data from 506 long-term CRC survivors and 1489 controls recruited from German population-based multi-regional studies. HRQOL was assessed with the European Organization for Research and Treatment of Cancer Quality of Life Core-30 (EORTC QLQ-C30) questionnaire. We estimated differences in the HRQOL of CRC survivors and controls with multiple regression, adjusted for age at survey, sex, and education, where appropriate. (3) Results: CRC survivors reported poorer social functioning but better health status/QOL than controls. CRC survivors, in general, had higher levels of symptom burden, and in particular diarrhea and constipation, regardless of demographic or clinical factors. In stratified analyses, HRQOL differed by age, sex, cancer type, and having a permanent stoma. (4) Conclusions: Although CRC survivors may have a comparable health status/QOL to controls 14-24 years after diagnosis, they still live with persistent bowel dysfunction that can negatively impact aspects of functioning. Healthcare providers should provide timely and adapted follow-up care to ameliorate potential long-term suffering.},
  language  = {en}
}
@article{KistThomaschewskiKecketal.2022,
  author    = {Kist, Markus and Thomaschewski, Michael and Keck, Yannick and Abdalla, Thaer S. A. and Zeissig, Sylke Ruth and Kleihues-van Tol, Kees and Wellner, Ulrich Friedrich and Keck, Tobias and Hoeppner, Jens and Hummel, Richard},
  title     = {Specifics of young gastric cancer patients: a population-based analysis of 46,110 patients with gastric cancer from the German Clinical Cancer Registry Group},
  series = {Cancers},
  volume    = {14},
  journal   = {Cancers},
  number    = {23},
  issn      = {2072-6694},
  doi       = {10.3390/cancers14235927},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-297473},
  year      = {2022},
  abstract  = {Introduction: 2-8\% of all gastric cancer occurs at a younger age, also known as early-onset gastric cancer (EOGC). The aim of the present work was to use clinical registry data to classify and characterize the young cohort of patients with gastric cancer more precisely. Methods: German Cancer Registry Group of the Society of German Tumor Centers—Network for Care, Quality and Research in Oncology (ADT)was queried for patients with gastric cancer from 2000-2016. An approach that stratified relative distributions of histological subtypes of gastric adenocarcinoma according to age percentiles was used to define and characterize EOGC. Demographics, tumor characteristics, treatment and survival were analyzed. Results: A total of 46,110 patients were included. Comparison of different groups of age with incidences of histological subtypes showed that incidence of signet ring cell carcinoma (SRCC) increased with decreasing age and exceeded pooled incidences of diffuse and intestinal type tumors in the youngest 20\% of patients. We selected this group with median age of 53 as EOGC. The proportion of female patients was lower in EOGC than that of elderly patients (43\% versus 45\%; p < 0.001). EOGC presented more advanced and undifferentiated tumors with G3/4 stages in 77\% versus 62\%, T3/4 stages in 51\% versus 48\%, nodal positive tumors in 57\% versus 53\% and metastasis in 35\% versus 30\% (p < 0.001) and received less curative treatment (42\% versus 52\%; p < 0.001). Survival of EOGC was significantly better (five-years survival: 44\% versus 31\% (p < 0.0001), with age as independent predictor of better survival (HR 0.61; p < 0.0001). Conclusion: With this population-based registry study we were able to objectively define a cohort of patients referred to as EOGC. Despite more aggressive/advanced tumors and less curative treatment, survival was significantly better compared to elderly patients, and age was identified as an independent predictor for better survival.},
  language  = {en}
}